<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Crimea Journal of Experimental and Clinical Medicine</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Crimea Journal of Experimental and Clinical Medicine</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Крымский журнал экспериментальной и клинической медицины</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2224-6444</issn>
   <issn publication-format="online">2224-6452</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">54939</article-id>
   <article-id pub-id-type="doi">10.29039/2224-6444-2021-11-3-85-92</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>ОБЗОРЫ</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>REVIEWS</subject>
    </subj-group>
    <subj-group>
     <subject>ОБЗОРЫ</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">POTENTIAL MARKERS OF RECURRENCY OF UROLITHIASIS DISEASE AND THE ROLE OF STONE FORMATION INHIBITORS IN RECURRENT CALCIUM OXALATE NEPHROLITHIASIS</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>ПОТЕНЦИАЛЬНЫЕ МАРКЕРЫ РЕЦИДИВИРОВАНИЯ МОЧЕКАМЕННОЙ БОЛЕЗНИ И РОЛЬ ИНГИБИТОРОВ КАМНЕОБРАЗОВАНИЯ ПРИ РЕЦИДИВИРУЮЩЕМ КАЛЬЦИЙ-ОКСАЛАТНОМ НЕФРОЛИТИАЗЕ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Буданов</surname>
       <given-names>А. А.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Budanov</surname>
       <given-names>A. A.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Медведев</surname>
       <given-names>В. Л.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Medvedev</surname>
       <given-names>V. L.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Курзанов</surname>
       <given-names>А. Н.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Kurzanov</surname>
       <given-names>A. N.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Быков</surname>
       <given-names>Илья Михайлович</given-names>
      </name>
      <name xml:lang="en">
       <surname>Bykov</surname>
       <given-names>I. M.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Басов</surname>
       <given-names>А. А.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Basov</surname>
       <given-names>A. A.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Русинова</surname>
       <given-names>Т. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Rusinova</surname>
       <given-names>T. V.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Кубанский государственный медицинский университет</institution>
    </aff>
    <aff>
     <institution xml:lang="en">The Kuban State Medical University</institution>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">ГБУЗ  «Научно-исследовательский  институт  –  Краевая  больница  №1  им.  проф.  С.В.  Очаповского»  Министерства здравоохранения Краснодарского края</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">ГБУЗ  «Научно-исследовательский  институт  –  Краевая  больница  №1  им.  проф.  С.В.  Очаповского»  Министерства здравоохранения Краснодарского края</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2022-11-08T15:46:36+03:00">
    <day>08</day>
    <month>11</month>
    <year>2022</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-11-08T15:46:36+03:00">
    <day>08</day>
    <month>11</month>
    <year>2022</year>
   </pub-date>
   <volume>11</volume>
   <issue>3</issue>
   <fpage>85</fpage>
   <lpage>92</lpage>
   <history>
    <date date-type="received" iso-8601-date="2022-11-07T00:00:00+03:00">
     <day>07</day>
     <month>11</month>
     <year>2022</year>
    </date>
   </history>
   <self-uri xlink:href="https://ma.cfuv.ru/site/page/show/docid/260468">https://ma.cfuv.ru/site/page/show/docid/260468</self-uri>
   <abstract xml:lang="ru">
    <p>Мочекаменная  болезнь  (почечнокаменная  болезнь,  нефролитиаз)  является  частым  заболеванием, лечение  которого  в  современное  время  является  серьёзной  задачей  систем  здравоохранения  не  только в  России,  но  и  во  всём  мире.  При  этом  камни  кальций-оксалатной  природы,  являются  наиболее  часто встречающимися конкрементами у пациентов с данной патологией – примерно в 70-80% случаев. Также стоит отметить, что данное заболевание не только обладает достаточно болезненными проявлениями и требует больших финансовых затрат для лечения, но и имеет сложный многофакторный многоступенчатый патогенез, понимание механизмов которого может дать ключ к разработке наиболее успешной терапии. Сам патогенез &#13;
состоит из нескольких этапов, таких как нуклеация с формированием центра кристаллизации, рост кристаллов, агрегация и их прикрепление к поверхности эпителиальных клеток. &#13;
Известно, что в организме человека имеются различные вещества, влияющие на процессы камнеобразования. Так, промоторы камнеобразования облегчают их кристаллизацию, а ингибиторы предотвращают её. Между промоторами  и  ингибиторами  имеется  тонкое  равновесие,  и  их  дисбаланс  зачастую  является  решающим фактором патогенеза. По химической природе ингибиторы могут быть как неорганическими, так и органическими (белки, гликозаминогликаны) веществами. Последние особенно привлекают внимание, так как при различных концентрациях они могут выступать как ингибиторами, так и промоторами камнеобразования. Для полного понимания  механизмов  образования  кальций-оксалатных  камней  в  данном  обзоре  проводится  анализ современных данных об ингибиторах рецидивирующего нефролитиаза и их роль в патофизиологии процесса образования почечных камней.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Nowadays urolithiasis (nephrolithiasis) is a common disease, which treatment is a serious task of health care ser- vices not only in Russia, but throughout the world. At the same time, stones of a calcium-oxalate nature are the most common stones in patients with this pathology – in about 70-80% of cases. It is also worth noting that this disease not only has rather painful manifestations, and its treatment requires large financial costs, but also has a complex multi- factorial multistage pathogenesis, understanding the mechanisms of which can provide a key to the development of the most successful therapy. Pathogenesis itself consists of several stages, such as nucleation with the formation of a crystallization center, crystal growth, aggregation and their attachment to the surface of epithelial cells.&#13;
It is known that the human body contains various substances that affect the processes of stone formation. Thus, stone formation promoters facilitate their crystallization, and inhibitors prevent it. There is a delicate balance between promoters and inhibitors, and their imbalance is often a decisive factor in pathogenesis. By their chemical nature, inhibitors can be both inorganic and organic (proteins, glycosaminoglycans) substances. The latter are especially attracting attention, since at various concentrations they can act as both inhibitors and promoters of stone formation. To fully understand the mechanisms of calcium oxalate stone formation, this review analyzes current data on inhibitors of recurrent nephrolithiasis and their role in the pathophysiology of the process of renal stone formation.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>нефролитиаз</kwd>
    <kwd>ингибиторы  камнеобразования</kwd>
    <kwd>кальций-оксалатные  камни</kwd>
    <kwd>белок Тамма-Хорсфалла</kwd>
    <kwd>нефрокальцин</kwd>
    <kwd>альбумин</kwd>
    <kwd>остеопонтин</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>nephrolithiasis</kwd>
    <kwd>inhibitors of stone formation</kwd>
    <kwd>calcium oxalate stones</kwd>
    <kwd>Tamm-Horsfall protein</kwd>
    <kwd>nephrocalcin</kwd>
    <kwd>albumin</kwd>
    <kwd>osteopontin</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Okada A., Ando R., Taguchi K. Identification of new urinary risk markers for urinary stones using a logistic model and  multinomial  logit  model.  Clinical  and  Experimental Nephrology.  2019;23(5):710-716.  doi:10.1007/s10157- 019-01693-x.</mixed-citation>
     <mixed-citation xml:lang="en">Okada A., Ando R., Taguchi K. Identification of new urinary risk markers for urinary stones using a logistic model and  multinomial  logit  model.  Clinical  and  Experimental Nephrology.  2019;23(5):710-716.  doi:10.1007/s10157- 019-01693-x.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Rimer  J.  D.,  Kolbach-Mandel  A.  M.,  Ward  M. D.,  Wesson  J.  A.  The  role  of  macromolecules  in  the formation of kidney stones. Urolithiasis. 2017;45(1):57-74. doi:10.1007/s00240-016-0948-8.</mixed-citation>
     <mixed-citation xml:lang="en">Rimer  J.  D.,  Kolbach-Mandel  A.  M.,  Ward  M. D.,  Wesson  J.  A.  The  role  of  macromolecules  in  the formation of kidney stones. Urolithiasis. 2017;45(1):57-74. doi:10.1007/s00240-016-0948-8.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Baumann J. M., Casella R. Prevention of Calcium Nephrolithiasis:  The  Influence  of  Diuresis  on  Calcium Oxalate Crystallization in Urine. Advances in Preventive Medicine. 2019;2019:1-8. doi:10.1155/ 2019/3234867.</mixed-citation>
     <mixed-citation xml:lang="en">Baumann J. M., Casella R. Prevention of Calcium Nephrolithiasis:  The  Influence  of  Diuresis  on  Calcium Oxalate Crystallization in Urine. Advances in Preventive Medicine. 2019;2019:1-8. doi:10.1155/ 2019/3234867.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Baumann  J.  M.,  Affolter  B.  The  paradoxical role  of  urinary  macromolecules  in  the  aggregation  of calcium  oxalate:  a  further  plea  to  increase  diuresis  in stone  metaphylaxis.  Urolithiasis.  2016;44(4):311-317. doi:10.1007/s00240-016-0863-z.</mixed-citation>
     <mixed-citation xml:lang="en">Baumann  J.  M.,  Affolter  B.  The  paradoxical role  of  urinary  macromolecules  in  the  aggregation  of calcium  oxalate:  a  further  plea  to  increase  diuresis  in stone  metaphylaxis.  Urolithiasis.  2016;44(4):311-317. doi:10.1007/s00240-016-0863-z.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Alelign  T,  Petros  B.  Kidney  Stone  Disease:  An Update  on  Current  Concepts.  Advances  in  Urology. 2018;2018:1-12. doi:10.1155/2018/3068365.</mixed-citation>
     <mixed-citation xml:lang="en">Alelign  T,  Petros  B.  Kidney  Stone  Disease:  An Update  on  Current  Concepts.  Advances  in  Urology. 2018;2018:1-12. doi:10.1155/2018/3068365.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Robertson W. G. Do «inhibitors of crystallisation» play any role in the prevention of kidney stones? A critique. Urolithiasis.  2017;45(1):43-56.  doi:10.1007/s00240-016- 0953-y.</mixed-citation>
     <mixed-citation xml:lang="en">Robertson W. G. Do «inhibitors of crystallisation» play any role in the prevention of kidney stones? A critique. Urolithiasis.  2017;45(1):43-56.  doi:10.1007/s00240-016- 0953-y.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Hattori C. M., Tiselius H. G., Heilberg I. P. Whey protein  and  albumin  effects  upon  urinary  risk  factors for  stone  formation.  Urolithiasis.  2017;45(5):421-428. doi:10.1007/s00240-017-0975-0.</mixed-citation>
     <mixed-citation xml:lang="en">Hattori C. M., Tiselius H. G., Heilberg I. P. Whey protein  and  albumin  effects  upon  urinary  risk  factors for  stone  formation.  Urolithiasis.  2017;45(5):421-428. doi:10.1007/s00240-017-0975-0.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Khan S. R, Canales B. K., Dominguez-Gutierrez P. R. Randall’s plaque and calcium oxalate stone formation: role  for  immunity  and  inflammation.  Native  Reviews Nephrology.  2021;17(6):417-433.  doi:10.1038/ s41581- 020-00392-1.</mixed-citation>
     <mixed-citation xml:lang="en">Khan S. R, Canales B. K., Dominguez-Gutierrez P. R. Randall’s plaque and calcium oxalate stone formation: role  for  immunity  and  inflammation.  Native  Reviews Nephrology.  2021;17(6):417-433.  doi:10.1038/ s41581- 020-00392-1.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Tanaka  Y.,  Okada  A.,  Maruyama  M.,  Tajiri  R., Sugino  T.,  Unno  R.,  Taguchi  K.,  Hamamoto  S.,  Ando R., Yoshimura M., Mori  Y., Kohri K., Yasui T. MP10-11 discovering spatial distribution and differential localization of  protein  matrix  in  calcium  oxalate  stones;  a  novel method  of  multifaceted  structure  analysis.  Journal  of Urology. 2020; 203(Supplement 4):129-130. doi:10.1097/ JU.0000000000000830.011.</mixed-citation>
     <mixed-citation xml:lang="en">Tanaka  Y.,  Okada  A.,  Maruyama  M.,  Tajiri  R., Sugino  T.,  Unno  R.,  Taguchi  K.,  Hamamoto  S.,  Ando R., Yoshimura M., Mori  Y., Kohri K., Yasui T. MP10-11 discovering spatial distribution and differential localization of  protein  matrix  in  calcium  oxalate  stones;  a  novel method  of  multifaceted  structure  analysis.  Journal  of Urology. 2020; 203(Supplement 4):129-130. doi:10.1097/ JU.0000000000000830.011.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ajeel M. A., Al-Mahdawi Z. M. M. Evaluation The role of Trefoil Factor 1 as early stage biomarker in patients with  Nephrolithiasis.  Tikrit  Journal  of  Pure  Science. 2018;23(9):16-19. doi:10.25130/tjps.23.2018.144.</mixed-citation>
     <mixed-citation xml:lang="en">Ajeel M. A., Al-Mahdawi Z. M. M. Evaluation The role of Trefoil Factor 1 as early stage biomarker in patients with  Nephrolithiasis.  Tikrit  Journal  of  Pure  Science. 2018;23(9):16-19. doi:10.25130/tjps.23.2018.144.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sayer  J.  A.  Progress  in  Understanding  the Genetics  of  Calcium-Containing  Nephrolithiasis.  Journal of American Society of Nephrology. 2017;28(3):748-759. doi:10.1681/ASN.2016050576.</mixed-citation>
     <mixed-citation xml:lang="en">Sayer  J.  A.  Progress  in  Understanding  the Genetics  of  Calcium-Containing  Nephrolithiasis.  Journal of American Society of Nephrology. 2017;28(3):748-759. doi:10.1681/ASN.2016050576.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Laffite G., Leroy C., Bonhomme C., Bonhomme- Coury L., Letavernier E., Daudon M., Frochot V., Haymann J.  P.,  Rouziиre  S.,  Lucas  I.  T.,  Bazin  D.,  Babonneau F.,  Abou-Hassan  A.  Calcium  oxalate  precipitation  by diffusion using laminar microfluidics: toward a biomimetic model of pathological microcalcifications. Lab on a Chip. 2016;16(7):1157-1160. doi:10.1039/c6lc00197a.</mixed-citation>
     <mixed-citation xml:lang="en">Laffite G., Leroy C., Bonhomme C., Bonhomme- Coury L., Letavernier E., Daudon M., Frochot V., Haymann J.  P.,  Rouziire  S.,  Lucas  I.  T.,  Bazin  D.,  Babonneau F.,  Abou-Hassan  A.  Calcium  oxalate  precipitation  by diffusion using laminar microfluidics: toward a biomimetic model of pathological microcalcifications. Lab on a Chip. 2016;16(7):1157-1160. doi:10.1039/c6lc00197a.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Berger G. K., Eisenhauer J., Vallejos A., Hoffmann B., Wesson J. A. Exploring mechanisms of protein influence on  calcium  oxalate  kidney  stone  formation.  Urolithiasis. 2021:1-10. doi:10.1007/s00240-021-01247-5.</mixed-citation>
     <mixed-citation xml:lang="en">Berger G. K., Eisenhauer J., Vallejos A., Hoffmann B., Wesson J. A. Exploring mechanisms of protein influence on  calcium  oxalate  kidney  stone  formation.  Urolithiasis. 2021:1-10. doi:10.1007/s00240-021-01247-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Attari V. E., Maddah A., Asl Z. S., Jalili M., Ardalan M. R., Mokari S. The association of serum uromodulin with allograft function and risk of urinary tract infection in kidney transplant recipients. Journal of Renal Injury Prevention. 2021;10(1):1-6. doi:10.34172/jrip.2021.02.</mixed-citation>
     <mixed-citation xml:lang="en">Attari V. E., Maddah A., Asl Z. S., Jalili M., Ardalan M. R., Mokari S. The association of serum uromodulin with allograft function and risk of urinary tract infection in kidney transplant recipients. Journal of Renal Injury Prevention. 2021;10(1):1-6. doi:10.34172/jrip.2021.02.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Khan  A.  Prevalence,  pathophysiological mechanisms and factors affecting urolithiasis. International Urology and Nephrology. 2018;50(5):799-806. doi:10.1007/ s11255-018-1849-2.</mixed-citation>
     <mixed-citation xml:lang="en">Khan  A.  Prevalence,  pathophysiological mechanisms and factors affecting urolithiasis. International Urology and Nephrology. 2018;50(5):799-806. doi:10.1007/ s11255-018-1849-2.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Micanovic R., LaFavers K., Garimella P. S., Wu X. R., El-Achkar T. M. Uromodulin (Tamm-Horsfall protein): guardian of urinary and systemic homeostasis. Nephrology Dialysis  Transplantation.  2020;35(1):33-43.  doi:10.1093/ ndt/gfy394.</mixed-citation>
     <mixed-citation xml:lang="en">Micanovic R., LaFavers K., Garimella P. S., Wu X. R., El-Achkar T. M. Uromodulin (Tamm-Horsfall protein): guardian of urinary and systemic homeostasis. Nephrology Dialysis  Transplantation.  2020;35(1):33-43.  doi:10.1093/ ndt/gfy394.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Schaeffer  C.,  Devuyst  O.,  Rampoldi  L. Uromodulin: Roles in Health and Disease. Annual Review of  Physiology.  2021;83:477-501.  doi:10.1146/annurev- physiol-031620-092817.</mixed-citation>
     <mixed-citation xml:lang="en">Schaeffer  C.,  Devuyst  O.,  Rampoldi  L. Uromodulin: Roles in Health and Disease. Annual Review of  Physiology.  2021;83:477-501.  doi:10.1146/annurev- physiol-031620-092817.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B18">
    <label>18.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Debroise  T.,  Sedzik  T.,  Vekeman  J.,  Su  Y., Bonhomme C., Tielens F. Morphology of calcium oxalate polyhydrates:  a  quantum  chemical  and  computational study.  Crystal  Growth  &amp;  Design.  2020;20(6):3807-3815. doi:10.1021/acs.cgd.0c00119.</mixed-citation>
     <mixed-citation xml:lang="en">Debroise  T.,  Sedzik  T.,  Vekeman  J.,  Su  Y., Bonhomme C., Tielens F. Morphology of calcium oxalate polyhydrates:  a  quantum  chemical  and  computational study.  Crystal  Growth  &amp;  Design.  2020;20(6):3807-3815. doi:10.1021/acs.cgd.0c00119.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B19">
    <label>19.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kelland  M.  A.,  Mady  M.  F.,  Lima-Eriksen  R. Kidney  stone  prevention:  dynamic  testing  of  edible calcium oxalate scale inhibitors. Crystal Growth &amp; Design. 2018;18(12):7441-7450. doi:10.1021/ acs.cgd.8b01173.</mixed-citation>
     <mixed-citation xml:lang="en">Kelland  M.  A.,  Mady  M.  F.,  Lima-Eriksen  R. Kidney  stone  prevention:  dynamic  testing  of  edible calcium oxalate scale inhibitors. Crystal Growth &amp; Design. 2018;18(12):7441-7450. doi:10.1021/ acs.cgd.8b01173.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B20">
    <label>20.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Blay V., Li M. C., Ho S. P., Stoller M. L., Hsieh H. P., Houston D. R. Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharmaceutica Sinica  B.  2020;10(7):1309-1320.  doi:10.1016/j. apsb.2019.09.008.</mixed-citation>
     <mixed-citation xml:lang="en">Blay V., Li M. C., Ho S. P., Stoller M. L., Hsieh H. P., Houston D. R. Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharmaceutica Sinica  B.  2020;10(7):1309-1320.  doi:10.1016/j. apsb.2019.09.008.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B21">
    <label>21.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Garcнa-Perdomo H. A., Solarte P. B., Espaсa P. P. Pathophysiology associated with forming urinary stones. Urologнa Colombiana. 2016;25(2):118-125. doi:10.1016/j. uroco.2015.12.013.</mixed-citation>
     <mixed-citation xml:lang="en">Garcna-Perdomo H. A., Solarte P. B., Espasa P. P. Pathophysiology associated with forming urinary stones. Urologna Colombiana. 2016;25(2):118-125. doi:10.1016/j. uroco.2015.12.013.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B22">
    <label>22.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Zhao M., Yang Y., Guo Z., Shao C., Sun H., Zhang Y., Sun Y., Liu Y., Song Y., Zhang L., Li Q., Liu J., Li M., Gao Y., Sun W. A Comparative Proteomics Analysis of Five Body Fluids: Plasma, Urine, Cerebrospinal Fluid, Amniotic Fluid,  and  Saliva.  Proteomics  -  Clinical  Application. 2018;12(6):1800008. doi:10.1002/prca.201800008.</mixed-citation>
     <mixed-citation xml:lang="en">Zhao M., Yang Y., Guo Z., Shao C., Sun H., Zhang Y., Sun Y., Liu Y., Song Y., Zhang L., Li Q., Liu J., Li M., Gao Y., Sun W. A Comparative Proteomics Analysis of Five Body Fluids: Plasma, Urine, Cerebrospinal Fluid, Amniotic Fluid,  and  Saliva.  Proteomics  -  Clinical  Application. 2018;12(6):1800008. doi:10.1002/prca.201800008.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B23">
    <label>23.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Priyadarshini,  Raizada  D.,  Kumar  P.,  Singh T., Pruthi T., Negi A., Nigam L., Subbarao N. Exploring the  modulatory  effect  of  albumin  on  calcium  phosphate crystallization.  Current  Science.  2019; 117(6):1083. doi:10.18520/cs/v117/i6/1083-1089.</mixed-citation>
     <mixed-citation xml:lang="en">Priyadarshini,  Raizada  D.,  Kumar  P.,  Singh T., Pruthi T., Negi A., Nigam L., Subbarao N. Exploring the  modulatory  effect  of  albumin  on  calcium  phosphate crystallization.  Current  Science.  2019; 117(6):1083. doi:10.18520/cs/v117/i6/1083-1089.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B24">
    <label>24.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Haley W. E., Enders F. T., Vaughan L. E., Mehta R. A., Thoman M. E., Vrtiska T. J., Krambeck A. E., Lieske J. C., Rule A. D. Kidney function after the first kidney stone event. Mayo Clinic Proceedings. 2016; 91(12):1744-1752. doi:10.1016/j.mayocp.2016.08.014.</mixed-citation>
     <mixed-citation xml:lang="en">Haley W. E., Enders F. T., Vaughan L. E., Mehta R. A., Thoman M. E., Vrtiska T. J., Krambeck A. E., Lieske J. C., Rule A. D. Kidney function after the first kidney stone event. Mayo Clinic Proceedings. 2016; 91(12):1744-1752. doi:10.1016/j.mayocp.2016.08.014.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B25">
    <label>25.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dobrek  L.  Physiological  and  pathophysiological implications  of  osteopontin  and  the  diagnostic  utility  of the  protein  in  kidney  diseases.  Journal  of  Pre-Clinical and  Clinical  Research.  2018;12(1):6-10.  doi:10.26444/ jpccr/87075.</mixed-citation>
     <mixed-citation xml:lang="en">Dobrek  L.  Physiological  and  pathophysiological implications  of  osteopontin  and  the  diagnostic  utility  of the  protein  in  kidney  diseases.  Journal  of  Pre-Clinical and  Clinical  Research.  2018;12(1):6-10.  doi:10.26444/ jpccr/87075.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B26">
    <label>26.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kaleta  B.  The  role  of  osteopontin  in  kidney diseases.  Inflammation  Research.  2019;68(2):93-102. doi:10.1007/s00011-018-1200-5.</mixed-citation>
     <mixed-citation xml:lang="en">Kaleta  B.  The  role  of  osteopontin  in  kidney diseases.  Inflammation  Research.  2019;68(2):93-102. doi:10.1007/s00011-018-1200-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B27">
    <label>27.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Wasgewatte Wijesinghe D. K., Mackie E. J., Pagel C. N. Normal inflammation and regeneration of muscle following injury require osteopontin from both muscle and non-muscle cells. Skelet Muscle. 2019;9(1):6. doi:10.1186/ s13395-019-0190-5.</mixed-citation>
     <mixed-citation xml:lang="en">Wasgewatte Wijesinghe D. K., Mackie E. J., Pagel C. N. Normal inflammation and regeneration of muscle following injury require osteopontin from both muscle and non-muscle cells. Skelet Muscle. 2019;9(1):6. doi:10.1186/ s13395-019-0190-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B28">
    <label>28.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bhardwaj R., Bhardwaj A., Tandon C., Dhawan D. K., Bijarnia R. K., Kaur T. Implication of hyperoxaluria on osteopontin  and  ER  stress  mediated  apoptosis  in  renal tissue  of  rats.  Experimental  and  Molecular  Pathology. 2017;102(3):384-390. doi:10.1016/j.yexmp.2017.04.002.</mixed-citation>
     <mixed-citation xml:lang="en">Bhardwaj R., Bhardwaj A., Tandon C., Dhawan D. K., Bijarnia R. K., Kaur T. Implication of hyperoxaluria on osteopontin  and  ER  stress  mediated  apoptosis  in  renal tissue  of  rats.  Experimental  and  Molecular  Pathology. 2017;102(3):384-390. doi:10.1016/j.yexmp.2017.04.002.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B29">
    <label>29.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Gleberzon J. S., Liao Y., Mittler S., Goldberg H. A., Grohe B. Incorporation of osteopontin peptide into kidney stone-related  calcium  oxalate  monohydrate  crystals: a  quantitative  study.  Urolithiasis.  2019;47(5):425-440. doi:10.1007/s00240-018-01105-x.</mixed-citation>
     <mixed-citation xml:lang="en">Gleberzon J. S., Liao Y., Mittler S., Goldberg H. A., Grohe B. Incorporation of osteopontin peptide into kidney stone-related  calcium  oxalate  monohydrate  crystals: a  quantitative  study.  Urolithiasis.  2019;47(5):425-440. doi:10.1007/s00240-018-01105-x.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B30">
    <label>30.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">O’Kell A. L., Lovett A. C., Canales B. K., Gower L. B., Khan S. R. Development of a two-stage model system to  investigate  the  mineralization  mechanisms  involved in  idiopathic  stone  formation:  stage  2  in  vivo  studies  of stone growth on biomimetic Randall’s plaque. Urolithiasis. 2019;47(4):335-346. doi:10.1007/s00240-018-1079-1.</mixed-citation>
     <mixed-citation xml:lang="en">O’Kell A. L., Lovett A. C., Canales B. K., Gower L. B., Khan S. R. Development of a two-stage model system to  investigate  the  mineralization  mechanisms  involved in  idiopathic  stone  formation:  stage  2  in  vivo  studies  of stone growth on biomimetic Randall’s plaque. Urolithiasis. 2019;47(4):335-346. doi:10.1007/s00240-018-1079-1.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B31">
    <label>31.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Martelli  C.,  Marzano  V.,  Iavarone  F.,  Huang  L., Vincenzoni  F.,  Desiderio  C.,  Messana  I.,  Beltrami  P., Zattoni F., Ferraro P. M., Buchholz N., Locci G., Faa G., Castagnola M., Gambaro G. Characterization of the Protein Components  of  Matrix  Stones  Sheds  Light  on  S100-A8 and S100-A9 Relevance in the Inflammatory Pathogenesis of  These  Rare  Renal  Calculi.  Journal  of  Urology. 2016;196(3):911-918.doi: 10.1016/j.juro.2016.04.064.</mixed-citation>
     <mixed-citation xml:lang="en">Martelli  C.,  Marzano  V.,  Iavarone  F.,  Huang  L., Vincenzoni  F.,  Desiderio  C.,  Messana  I.,  Beltrami  P., Zattoni F., Ferraro P. M., Buchholz N., Locci G., Faa G., Castagnola M., Gambaro G. Characterization of the Protein Components  of  Matrix  Stones  Sheds  Light  on  S100-A8 and S100-A9 Relevance in the Inflammatory Pathogenesis of  These  Rare  Renal  Calculi.  Journal  of  Urology. 2016;196(3):911-918.doi: 10.1016/j.juro.2016.04.064.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B32">
    <label>32.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bennett D., Salvini M., Fui A., Cillis G., Cameli P., Mazzei M. A., Fossi A., Refini R. M., Rottoli P. Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation. 2019;42(2):463-470. doi:10.1007/ s10753-018-00955-2.</mixed-citation>
     <mixed-citation xml:lang="en">Bennett D., Salvini M., Fui A., Cillis G., Cameli P., Mazzei M. A., Fossi A., Refini R. M., Rottoli P. Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation. 2019;42(2):463-470. doi:10.1007/ s10753-018-00955-2.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B33">
    <label>33.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sohgaura A., Bigoniya P. A review on epidemiology and  etiology  of  renal  stone.  American  Journal  of  Drug Discovery  and  Development.  2017;7(2):54-62.  doi: 10.3923/ajdd.2017.54.62.</mixed-citation>
     <mixed-citation xml:lang="en">Sohgaura A., Bigoniya P. A review on epidemiology and  etiology  of  renal  stone.  American  Journal  of  Drug Discovery  and  Development.  2017;7(2):54-62.  doi: 10.3923/ajdd.2017.54.62.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B34">
    <label>34.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Marques S., Santos S., Fremin K., Fogo A. B. A case of oxalate nephropathy: when a single cause is not crystal clear. American Journal of Kidney Diseases. 2017; 70(5): 722-724. doi:10.1053/j.ajkd.2017.05.022.</mixed-citation>
     <mixed-citation xml:lang="en">Marques S., Santos S., Fremin K., Fogo A. B. A case of oxalate nephropathy: when a single cause is not crystal clear. American Journal of Kidney Diseases. 2017; 70(5): 722-724. doi:10.1053/j.ajkd.2017.05.022.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B35">
    <label>35.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Robinson T. E., Hughes E. AB., Wiseman O. J., Stapley S. A., Cox S. C., Grover L. M. Hexametaphosphate as a potential therapy for the dissolution and prevention of  kidney  stones.  Journal  of  Materials  Chemistry  B. 2020;8(24):5215-5224. doi:10.1039/d0tb00343c.</mixed-citation>
     <mixed-citation xml:lang="en">Robinson T. E., Hughes E. AB., Wiseman O. J., Stapley S. A., Cox S. C., Grover L. M. Hexametaphosphate as a potential therapy for the dissolution and prevention of  kidney  stones.  Journal  of  Materials  Chemistry  B. 2020;8(24):5215-5224. doi:10.1039/d0tb00343c.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B36">
    <label>36.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Felz S., Neu T. R., van Loosdrecht M. CM., Lin Y.  Aerobic  granular  sludge  contains  Hyaluronic  acid- like  and  sulfated  glycosaminoglycans-like  polymers. Water  Research.  2020;169:115291.  doi:10.1016/j. watres.2019.115291.</mixed-citation>
     <mixed-citation xml:lang="en">Felz S., Neu T. R., van Loosdrecht M. CM., Lin Y.  Aerobic  granular  sludge  contains  Hyaluronic  acid- like  and  sulfated  glycosaminoglycans-like  polymers. Water  Research.  2020;169:115291.  doi:10.1016/j. watres.2019.115291.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B37">
    <label>37.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Mazzucco  A.  Hyaluronic  Acid:  Evaluation  of Efficacy  with  Different  Molecular  Weights.  International Journal  of  Chemistry  Research  2018;1(1):13-18. doi:10.18689/ijcr-1000103 .</mixed-citation>
     <mixed-citation xml:lang="en">Mazzucco  A.  Hyaluronic  Acid:  Evaluation  of Efficacy  with  Different  Molecular  Weights.  International Journal  of  Chemistry  Research  2018;1(1):13-18. doi:10.18689/ijcr-1000103 .</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B38">
    <label>38.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Manzoor  M.  A.  P.,  Agrawal  A.  K.,  Singh  B., Mujeeburahiman  M.,  Rekha  P.  D.  Morphological characteristics and microstructure of kidney stones using synchrotron radiation μCT reveal the mechanism of crystal growth  and  aggregation  in  mixed  stones.  PLoS  One. 2019;3(14):e0214003. doi:10.1371/journal.pone.0214003.</mixed-citation>
     <mixed-citation xml:lang="en">Manzoor  M.  A.  P.,  Agrawal  A.  K.,  Singh  B., Mujeeburahiman  M.,  Rekha  P.  D.  Morphological characteristics and microstructure of kidney stones using synchrotron radiation μCT reveal the mechanism of crystal growth  and  aggregation  in  mixed  stones.  PLoS  One. 2019;3(14):e0214003. doi:10.1371/journal.pone.0214003.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B39">
    <label>39.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sшnder  S.  L.,  Boye  T.  L.,  Tцlle  R.,  Dengjel  J., Maeda  K.,  Jддttelд  M.,  Simonsen  A.  C.,  Jaiswal  J.  K., Nylandsted  J.  Annexin  A7  is  required  for  ESCRT  III- mediated  plasma  membrane  repair.  Scientific  Reports. 2019;9(1):1-12. doi:10.1038/s41598-019-43143-4.</mixed-citation>
     <mixed-citation xml:lang="en">Sshnder  S.  L.,  Boye  T.  L.,  Tclle  R.,  Dengjel  J., Maeda  K.,  Jddtteld  M.,  Simonsen  A.  C.,  Jaiswal  J.  K., Nylandsted  J.  Annexin  A7  is  required  for  ESCRT  III- mediated  plasma  membrane  repair.  Scientific  Reports. 2019;9(1):1-12. doi:10.1038/s41598-019-43143-4.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B40">
    <label>40.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Grewal  T.,  Rentero  C.,  Enrich  C.,  Wahba  M., Raabe C. A., Rescher U. Annexin Animal Models-From Fundamental  Principles  to  Translational  Research. Internation Journal of Molecular Science. 2021;22(7):3439. doi:10.3390/ijms22073439.</mixed-citation>
     <mixed-citation xml:lang="en">Grewal  T.,  Rentero  C.,  Enrich  C.,  Wahba  M., Raabe C. A., Rescher U. Annexin Animal Models-From Fundamental  Principles  to  Translational  Research. Internation Journal of Molecular Science. 2021;22(7):3439. doi:10.3390/ijms22073439.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B41">
    <label>41.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bjшrklund G., Svanberg E., Dadar M., Card D. J., Chirumbolo  S.,  Harrington  D.  J.,  Aaseth  J.  The  Role  of Matrix Gla Protein (MGP) in Vascular Calcification. Current Medical Chemistry. 2020;27(10):1647-1660. doi:10.2174/0 929867325666180716104159.</mixed-citation>
     <mixed-citation xml:lang="en">Bjshrklund G., Svanberg E., Dadar M., Card D. J., Chirumbolo  S.,  Harrington  D.  J.,  Aaseth  J.  The  Role  of Matrix Gla Protein (MGP) in Vascular Calcification. Current Medical Chemistry. 2020;27(10):1647-1660. doi:10.2174/0 929867325666180716104159.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B42">
    <label>42.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Gheorghe S. R., Crăciun A. M. Matrix Gla protein in  tumoral  pathology.  Medicine  and  Pharmacy  Reports. 2016;89(3):319-21. doi:10.15386/cjmed-579.</mixed-citation>
     <mixed-citation xml:lang="en">Gheorghe S. R., Crăciun A. M. Matrix Gla protein in  tumoral  pathology.  Medicine  and  Pharmacy  Reports. 2016;89(3):319-21. doi:10.15386/cjmed-579.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B43">
    <label>43.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ahmad S., Jan A. T., Baig M. H., Lee E. J., Choi I. Matrix gla protein: An extracellular matrix protein regulates myostatin  expression  in  the  muscle  developmental program.  Life  Sciences.  2017;172:55-63.  doi:10.1016/j. lfs.2016.12.011.</mixed-citation>
     <mixed-citation xml:lang="en">Ahmad S., Jan A. T., Baig M. H., Lee E. J., Choi I. Matrix gla protein: An extracellular matrix protein regulates myostatin  expression  in  the  muscle  developmental program.  Life  Sciences.  2017;172:55-63.  doi:10.1016/j. lfs.2016.12.011.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B44">
    <label>44.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Barrett H., O’Keeffe M., Kavanagh E., Walsh M., O’Connor  E.  M.  Is  Matrix  Gla  Protein  Associated  with Vascular  Calcification?  A  Systematic  Review.  Nutrients. 2018;10(4):415. doi:10.3390/nu10040415.</mixed-citation>
     <mixed-citation xml:lang="en">Barrett H., O’Keeffe M., Kavanagh E., Walsh M., O’Connor  E.  M.  Is  Matrix  Gla  Protein  Associated  with Vascular  Calcification?  A  Systematic  Review.  Nutrients. 2018;10(4):415. doi:10.3390/nu10040415.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B45">
    <label>45.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Borgen P. O., Reikeras O. Prothrombin fragment F1+2  in  plasma  and  urine  during  total  hip  arthroplasty. Journal  of  Orthopaedics.  2017;14(4):475-479. doi:10.1016/j.jor.2017.08.001.</mixed-citation>
     <mixed-citation xml:lang="en">Borgen P. O., Reikeras O. Prothrombin fragment F1+2  in  plasma  and  urine  during  total  hip  arthroplasty. Journal  of  Orthopaedics.  2017;14(4):475-479. doi:10.1016/j.jor.2017.08.001.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B46">
    <label>46.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sassanarakkit S., Peerapen P., Thongboonkerd V.  StoneMod:  a  database  for  kidney  stone  modulatory proteins  with  experimental  evidence.  Scientific  Reports. 2020;10(1):15109. doi:10.1038/s41598-020-71730-3.</mixed-citation>
     <mixed-citation xml:lang="en">Sassanarakkit S., Peerapen P., Thongboonkerd V.  StoneMod:  a  database  for  kidney  stone  modulatory proteins  with  experimental  evidence.  Scientific  Reports. 2020;10(1):15109. doi:10.1038/s41598-020-71730-3.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B47">
    <label>47.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Stober V. P., Lim Y. P., Opal S., Zhuo L., Kimata K., Garantziotis S. Inter-α-inhibitor Ameliorates Endothelial Inflammation  in  Sepsis.  Lung.  2019;197(3):361-369. doi:10.1007/s00408-019-00228-1.</mixed-citation>
     <mixed-citation xml:lang="en">Stober V. P., Lim Y. P., Opal S., Zhuo L., Kimata K., Garantziotis S. Inter-α-inhibitor Ameliorates Endothelial Inflammation  in  Sepsis.  Lung.  2019;197(3):361-369. doi:10.1007/s00408-019-00228-1.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B48">
    <label>48.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Laube  N.,  Klein  F.,  Bernsmann  F.  Kinetics  of calcium  oxalate  crystal  formation  in  urine.  Urolithiasis. 2017;45(2):151-157. doi:10.1007/s00240-016-0900-y.</mixed-citation>
     <mixed-citation xml:lang="en">Laube  N.,  Klein  F.,  Bernsmann  F.  Kinetics  of calcium  oxalate  crystal  formation  in  urine.  Urolithiasis. 2017;45(2):151-157. doi:10.1007/s00240-016-0900-y.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
